Sales of Drugs for Chronic Conditions to Accelerate Demand for Active Pharmaceutical Ingredients, says TMR Date: 03-16-2017 07:19 PM CET Category: Health & Medicine Press release from: Transparency Market Research - Medical Devices
The key players defining the competitive landscape of the global active pharmaceutical ingredient market as of 2015 were Teva Pharmaceutical Industries Ltd., Zhejiang Medicine Co., Ltd and Zhejiang NHU Co., Ltd., and North China Pharmaceutical Group Corp. (NCPC) and Northeast Pharmaceutical Group Co., Ltd. A critical analysis of the market suggests, these players will expand their market presence through meaningful mergers and acquisitions. The intense competition in the overall market is also being fueled by the high fixed costs and exit costs. As these expenditures for companies continue to remain high, players will focus on increasing their research and development activities to deliver result-oriented drugs. API Sales Gain Momentum with Surging Healthcare Expenditure The increasing healthcare budgets in recent years have been the undercurrent for the revenues flowing into the active pharmaceutical ingredient market. With exponentially growing demand for drugs, the consumption of active pharmaceutical ingredient has also increased by leaps and bounds. “Considering the population explosion, technological advancements, and ongoing scientific research projects the development of drugs will present effective solutions to a range of chronic diseases such as cancer, cardiovascular conditions, metabolic disorders, musculoskeletal disorders, and for other therapeutic uses,� says a TMR analyst. The demand for drugs to treat the aging population will definitely boost the sale of active pharmaceutical ingredients that are popularly used for manufacturing drug products. Due to a growing pool of geriatrics in Europe and North America, these regions are primarily driving the active pharmaceutical ingredient market. Improving access to healthcare and the growing demand for pharmaceuticals in Asia Pacific and Rest of the World are likely to create lucrative growth opportunities for the overall market. Furthermore, increasing investments by manufacturers, especially in India, to adhere to the guidelines set by the U.S. FDA is also winning them big contracts, thereby increasing foreign earnings. Download Exclusive Brochure of This Report : www.transparencymarketresearch.com/sample/sample.php?flag...
Seite 1 / 3